MedImmune

AstraZeneca, Acerta Pharma, MedImmune to present at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego

27 scientific presentations, including long-term data from Calquence in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic…

5 years ago

AstraZeneca and MedImmune present results from Phase III clinical trial of moxetumomab pasudotox in patients with hairy cell leukaemia

Trial meets the primary endpoint of durable complete response Majority of patients who had a complete response had no evidence…

6 years ago

AstraZeneca: US FDA approval for Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer

Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2…

6 years ago

AstraZeneca Phase III PACIFIC trial: Imfinzi demonstrated statistically-significant and clinically-meaningful improvement in PFS

Imfinzi improves progression-free survival (PFS) by more than 11 months compared to standard of care and is the first medicine…

7 years ago

MedImmune and Sanofi Pasteur to jointly develop and commercialise respiratory syncytial virus monoclonal antibody

LONDON, 03-Mar-2017 — /EuropaWire/ — MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division…

7 years ago

AstraZeneca and MedImmune presented encouraging results from their novel combination-focused immuno-oncology portfolio at ASCO Annual Meeting 2015

LONDON, 2-6-2015 — /EuropaWire/ — AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results…

9 years ago

AstraZeneca’s global biologics research and development arm MedImmune completed its acquisition of US-based Amplimmune for $225M plus $275M based on predetermined milestones

London, United Kingdom, 10-10-2013 — /EuropaWire/ — AstraZeneca today announced that on 4 October MedImmune, its global biologics research and development arm,…

11 years ago

MedImmune, NGM Biopharmaceuticals in exclusive agreement to discover, develop and commercialise therapies for diabetes and obesity

25-6-2013 — /europawire.eu/ — AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have…

11 years ago

AstraZeneca selects Cambridge Biomedical Campus for its new global R&D centre and corporate headquarters

Move brings AstraZeneca’s small molecule and MedImmune’s biologics research and development together at purpose-built facility on Cambridge Biomedical Campus 21-6-2013…

11 years ago